CD44 and breast carcinoma: To further validate TF expression on CSCs, we also used a CD44-based human CD24 negative CD44 positive (CD24- CD44+) breast cancer stem cell isolation protocol to isolate CD24- CD44+ CSCs from the TNBC line (MDA-MB-231) and patient-derived human breast cancer cells.